Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=4&sort=-funder
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1405&sort=-funder", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=5&sort=-funder", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=3&sort=-funder" }, "data": [ { "type": "Grant", "id": "10673", "attributes": { "award_id": "1R01AI169537-01A1", "title": "Human coronavirus infection of the nasal epithelium", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 26420, "first_name": "MARY KATHERINE", "last_name": "Bradford", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-09-20", "end_date": "2027-07-31", "award_amount": 727886, "principal_investigator": { "id": 22556, "first_name": "Noam A", "last_name": "Cohen", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1488, "ror": "https://ror.org/03j05zz84", "name": "Philadelphia VA Medical Center", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 20971, "first_name": "Susan R", "last_name": "Weiss", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 232, "ror": "https://ror.org/00b30xv10", "name": "University of Pennsylvania", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 emerged in China in late 2019, resulting in the COVID-19 pandemic. Like SARS-CoV (2002) and Middle East respiratory syndrome (MERS)-CoV (2012), SARS-CoV-2 can progress to cause lethal pneumonia. In contrast, infections with “common” respiratory CoVs (NL63, 229E, OC43) are largely limited to the upper respiratory tract. Furthermore, SARS-CoV-2 and in particular the omicron variant, can sometimes cause primarily upper respiratory infections. Thus, despite their highly conserved genome structure and shared replication schemes, human CoVs induce varying degrees of disease. Respiratory CoVs initiate infection through the nose, though few studies have addressed CoV infection of the nasal epithelium. We have an established cryobank of nasal epithelial cells from over 1000 genetically characterized individuals capable of being expanded and grown as air liquid interface (ALI) cultures, recapitulating the nasal respiratory epithelium. Our preliminary studies demonstrate that SARS-2 (and its emerging variants), MERS and NL63 all productively infect these cultures. However, NL63 only replicates at a lower temperature (33C), infects single cells rather than clusters (evinced by SARS-2/MERS) and causes a more cytopathic effect than SARS-2 or MERS, suggesting it may induce a robust local immune response thereby limiting its replication to the upper respiratory tract or stimulating an adaptive immune response prior to infecting the lower airway. One COVID-19 risk locus includes the leucine zipper transcription factor-like 1 gene (LZTFL1), which we show is highly expressed in ciliated nasal cells, with ubiquitous expression throughout the cytoplasm. Our preliminary data of SARS-CoV-2 infected cultures genotyped for the high vs low-risk LZTFL1 polymorphisms demonstrate that LZTFL1 could play a role in variability of SARS-CoV-2 spread. In addition, polymorphisms in OAS1, a sensor of double-stranded viral RNA that initiates the antiviral RNase L pathway, have been linked to COVID-19 resistance. We have extensive experience in this pathway and recently reported that SARS-CoV-2 activates RNase L while MERS-CoV shuts it down. Based on these and other data, we hypothesize that pathogenic outcomes of CoV infections are reflected in viral biology in the nasal epithelium. Thus, using a battery of diverse CoVs we will assess differences in cell entry and spread, optimal temperature for viral replication and shedding as well as host nasal cell responses to each CoV. We propose to use our biobank to identify host and viral factors affecting the establishment of infection, host cytokine and nasal antiviral responses and the contribution of polymorphisms in LZTFL1 and OAS1 genes in the outcome of infection. Our complementary expertise in coronavirus biology (Weiss) and nasal pathophysiology (Cohen) uniquely positions us to address these Aims. This work will contribute to understanding nasal CoV infection, the divergence of lethal and common CoVs as well as variation in clinical course among SARS-CoV-2 infections, and may lead to novel targeted prophylaxis or therapeutic strategies targeting the nose, the site of initial contact.", "keywords": [ "2019-nCoV", "Address", "Affect", "Air", "Amino Acid Sequence", "Antiviral Response", "Biological", "Biology", "COVID-19", "COVID-19 pandemic", "COVID-19 risk", "Cell Line", "Cell membrane", "Cells", "China", "Clinical", "Complement", "Coronavirus", "Coronavirus Infections", "Cytopathology", "Cytoplasm", "Data", "Disease", "Disease Outbreaks", "Epithelial", "Epithelial Cells", "Functional disorder", "Future", "Genes", "Genetic Polymorphism", "Genetic Transcription", "Genome", "Genotype", "Human", "Immune response", "Individual", "Infection", "Kinetics", "Lead", "Leucine Zippers", "Link", "Liquid substance", "Lung", "Lung infections", "Middle East Respiratory Syndrome", "Middle East Respiratory Syndrome Coronavirus", "Modeling", "Nasal Epithelium", "Nitric Oxide", "Nose", "Outcome", "Pathogenicity", "Pathway interactions", "Pattern", "Phenotype", "Play", "Pneumonia", "Positioning Attribute", "Primary Infection", "Production", "Prophylactic treatment", "Protein Isoforms", "Proteins", "Reporting", "Resistance", "Resources", "Ribonucleases", "Risk", "Role", "Route", "SARS coronavirus", "SARS-CoV-2 infection", "SARS-CoV-2 variant", "Scheme", "Severities", "Severity of illness", "Site", "Structure", "TMPRSS2 gene", "Temperature", "Testing", "Therapeutic", "Upper Respiratory Infections", "Upper respiratory tract", "Variant", "Viral", "Virus", "Virus Replication", "Virus Shedding", "Work", "adaptive immune response", "airway epithelium", "alveolar type II cell", "antimicrobial peptide", "base", "biobank", "cell type", "cold temperature", "cytokine", "design", "disorder risk", "experience", "genome wide association study", "genomic locus", "human coronavirus", "novel", "prevent", "respiratory", "response", "risk variant", "sensor", "single-cell RNA sequencing", "transcription factor", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "10789", "attributes": { "award_id": "1I01HX003571-01A1", "title": "Maintaining Preventive Care during Public Health Emergencies through Effective Coordination", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-10-01", "end_date": "2024-09-30", "award_amount": null, "principal_investigator": { "id": 26865, "first_name": "SYLVIA J.", "last_name": "HYSONG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1685, "ror": "", "name": "MICHAEL E DEBAKEY VA MEDICAL CENTER", "address": "", "city": "", "state": "TX", "zip": "", "country": "United States", "approved": true }, "abstract": "BACKGROUND. Screening lies at the heart of preventive care. However, COVID-19 has dramatically disrupted routine screening efforts, resulting in excess veteran mortality not directly attributable to COVID-19. Screening rates at VA during COVID have varied markedly by facility and clinical condition. This is illustrated in cancer and mental health screening; cross-facility variability exists for each, suggesting susceptibilities in the capacity and workflow of the screening and referral process. To better understand these susceptibilities and identify new practices to mitigate interrupted care, we propose a qualitative study comparing facilities that exhibited high, low, and highly variable performance (respectively) in screening rates before and during the pandemic. SIGNIFICANCE. Disruptions to preventive screening lead to excess veteran mortality. Therefore, caring for veterans’ regular primary care (PC) needs while fulfilling our Fourth Mission (emergency preparedness) requires top-notch coordination and nimble teamwork from all clinical personnel. Our study will identify the systematic strategies and coordination patterns between primary and specialty care that differentiate successful facilities from struggling ones. Our findings will help design new or adapt existing workflows and interventions for coordination, shaping how screening and preventive care is delivered during and beyond COVID-19. Our study directly addresses: a) this solicitation’s goals; b) HSR&D’s clinical priorities; c) VA’s strategic plan goals for highly reliable care; and d) ORD real-world research impact priorities. SPECIFIC AIMS. Using cancer and mental health screening rates as exemplars, we propose to (1) Compare how PACTs from VHA facilities of varying screening performance patterns (high, low, improving, plummeting, variable) during the COVID-19 pandemic coordinated (a) as a team to conduct screening services, and (b) with specialty care teams at their facility to conduct screening services; and (2) Compare team, facility, and system- based barriers, facilitators, and strategies for continuing screening services during the COVID-19 pandemic amongst PACTs from VHA facilities of varying screening performance patterns during that period. METHOD. Design and Participants. This multi-method study consists of qualitative analysis of interviews and focus groups with primary care personnel, leadership, and patients at 10 VA Medical Centers (VAMCs). Site Selection. We will select study sites using a purposive stratified approach based on site rurality, COVID-19 caseload at the beginning of the pandemic, and performance on five outpatient clinical performance indicators of cancer and mental health screening. Sites will be categorized into one of five screening performance groups: high performers, low performers, improvers, plummeters, and highly variable. Procedure. Using data from prior research by the PI, we will create process maps for each performance measure to create a baseline for comparison to the process used since the pandemic began. We will interview the ACOS for primary care at each site to update the map to reflect the currently used process. We will conduct focus groups with PC and relevant specialty care clinicians to elicit themes regarding clinician coordination patterns (e.g., handoffs), strategies, and barriers/facilitators to screening during COVID (Aims 1- 3). We will also conduct patient interviews to examine their screening experience during this period, for context. Data Analysis: All interview and focus groups will be audio-recorded, transcribed, and enhanced by field notes. We will analyze clinician focus group transcripts and field notes using iterative, rapid analysis. Patient semi- structured interviews will be analyzed using inductive/deductive content analysis. NEXT STEPS/IMPLEMENTATION. We will share our findings, including site-specific recommendations, locally with key stakeholders at participating sites, and nationally through the Office of Primary Care-Mental Health Integration program and the VA National Women Veterans Oncology System of Excellence.", "keywords": [ "Accountability", "Address", "Adopted", "American", "Behavior", "COVID-19", "COVID-19 pandemic", "Caring", "Cause of Death", "Chronic", "Clinic", "Clinical", "Colon", "Complex", "Country", "Data", "Data Analyses", "Detection", "Diagnosis", "Disease", "Disease Management", "Drops", "Early treatment", "Emergency Situation", "Ensure", "Exhibits", "Focus Groups", "Future", "Goals", "Health", "Health Personnel", "Healthcare", "Heart", "Human Resources", "Individual", "Interruption", "Intervention", "Interview", "Lead", "Leadership", "Malignant Neoplasms", "Maps", "Measures", "Medical center", "Mental Depression", "Mental Health", "Mental Health Services", "Mental disorders", "Methods", "Mission", "Modeling", "Oncology", "Outcome", "Outpatients", "Participant", "Patients", "Pattern", "Performance", "Persons", "Post-Traumatic Stress Disorders", "Predisposition", "Prevention", "Preventive care", "Preventive screening", "Preventive service", "Primary Health Care", "Procedures", "Process", "Public Health", "Quality of Care", "Readiness", "Recommendation", "Research", "Resources", "Role", "Services", "Shapes", "Site", "Specialist", "Strategic Planning", "Structure", "Symptoms", "System", "Testing", "Time", "Touch sensation", "Transcript", "Update", "Variant", "Veterans", "Woman", "Work", "base", "breast and cervical cancer screening", "coronavirus disease", "design", "exhaust", "experience", "improved", "medical specialties", "mortality", "notch protein", "pandemic disease", "prevent", "programs", "public health emergency", "routine screening", "rurality", "screening", "screening services", "telehealth", "tv watching" ], "approved": true } }, { "type": "Grant", "id": "5621", "attributes": { "award_id": "3K24AI150991-02S1", "title": "Clinical Impacts of Heterogeneous Interferon Responses to Viral Infection by Asthmatic Airway Epithelium", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 19452, "first_name": "Timothy A.", "last_name": "Gondre-Lewis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-07-01", "end_date": "2022-01-31", "award_amount": 67232, "principal_investigator": { "id": 19453, "first_name": "JASON S", "last_name": "DEBLEY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 732, "ror": "https://ror.org/01njes783", "name": "Seattle Children's Hospital", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Asthma exacerbations among U.S children result in 640,000 emergency department visits and 14 million missed school days annually. Viral infections trigger the majority of exacerbations in children, of which human rhinoviruses (HRV) are the most common. The airway epithelium plays central roles in regulating inflammation, airway remodeling responses, and innate immune responses to infection. The most striking response of airway epithelial cells (AECs) to viral infection is expression of type I and III interferons (IFN I/III) and IFN stimulated genes (ISG). Some have reported deficient IFN I/III responses to viral infection by asthmatic AECs and postulated that deficient epithelial IFN responses to viruses predispose to exacerbations, whereas others have not observed differences in AEC IFN responses to viruses between asthmatic and healthy AECs. In our unique cohort of well characterized asthmatic and healthy children, from whom we obtain bronchial and nasal AECs and conduct mechanistic experiments using air-liquid-interface organotypic culture models, we have observed significant heterogeneity in IFN I/III responses to HRV and RSV infection. For example, among our asthmatic AEC donors we have noted associations between high type I/III IFN responses and lower donor lung function, as well as distinct subgroups of exacerbation prone asthmatics with deficient IFN I/III responses to HRV. Heterogeneity in AEC IFN I/III responses to viral infections may be explained by polymorphisms in genes coding for viral sensors and/or key steps in signal transduction pathways upstream of IFN I and III. The overall goal my research program is to understand how airway epithelial responses influence viral-triggered exacerbations and airway remodeling mechanisms in asthmatic children. In the first aim, using primary cells from children with asthma we will test our hypothesis that polymorphisms in genes coding for viral sensors, and/or key steps in signal transduction pathways upstream of IFN responses, contribute to heterogeneity in IFN I/III responses to HRV infection by AECs from asthmatic children. In the second aim, we will prospectively follow a cohort of asthmatic children to test our hypothesis that deficient AEC IFN I/III responses to HRV are associated with a greater incidence of viral-triggered exacerbations in AEC donors. In the final aim, we will test our hypothesis that excessively high IFN I/III responses by asthmatic AECs to HRV are associated with lung function decline among AEC donors, and we will interrogate potential mechanisms whereby excessively high IFN I/III responses may promote proliferation and activation of lung stromal cells. The studies conducted in my research program and unique resource of primary airway epithelial cells from clinically well characterized asthmatic children provide an exceptional training environment for young investigators dedicated to a career in mechanistic patient-oriented research to learn translational research techniques to investigate the role of the airway epithelium in pediatric lung diseases and viral infection.", "keywords": [ "Adrenal Cortex Hormones", "Air", "Asthma", "Biological", "Biological Models", "Cell Culture Techniques", "Cell Line", "Cell model", "Cells", "Child", "Childhood", "Childhood Asthma", "Clinical", "Code", "Emergency department visit", "Environment", "Epithelial", "Epithelial Cells", "Fibroblasts", "Frequencies", "Gene Expression", "Genes", "Genetic Polymorphism", "Goals", "Heterogeneity", "Hospitalization", "Human", "Incidence", "Infection", "Inflammation", "Inhalation", "Innate Immune Response", "Interferons", "Learning", "Liquid substance", "Lung", "Lung diseases", "Modeling", "Morbidity - disease rate", "Myofibroblast", "Natural History", "Nose", "Pathogenesis", "Patients", "Phenotype", "Play", "Primary Infection", "Regulation", "Reporting", "Research", "Research Personnel", "Research Technics", "Resources", "Respiratory Syncytial Virus Infections", "Rhinovirus", "Rhinovirus infection", "Risk", "Role", "Schools", "Series", "Signal Transduction Pathway", "Stromal Cells", "Subgroup", "Techniques", "Testing", "Time", "Training", "Translational Research", "Viral", "Virus", "Virus Diseases", "Virus Replication", "airway epithelium", "airway remodeling", "asthma exacerbation", "asthmatic", "asthmatic airway", "asthmatic patient", "base", "career", "cohort", "cost", "cytokine", "experimental study", "functional decline", "loss of function", "patient oriented", "patient oriented research", "prevent", "programs", "prospective", "pulmonary function", "pulmonary function decline", "response", "sensor", "translational study" ], "approved": true } }, { "type": "Grant", "id": "10697", "attributes": { "award_id": "1I01RX003639-01A2", "title": "Home-Based Exercise Tele-Rehabilitation in High-Risk Veterans: Impact of COVID-19 Exposure and Socioeconomic Factors", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2022-10-01", "end_date": "2026-09-30", "award_amount": null, "principal_investigator": { "id": 26753, "first_name": "KRISANN K", "last_name": "OURSLER", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 26754, "first_name": "ALICE S.", "last_name": "RYAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1532, "ror": "https://ror.org/036a0e562", "name": "Baltimore VA Medical Center", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } }, { "type": "Grant", "id": "5391", "attributes": { "award_id": "5R43AI157534-02", "title": "Humanization of ACE2 and Associated Priming Proteases in New Mouse Models for Downstream Disease and Therapy Investigations of COVID-19", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 18870, "first_name": "Erik J.", "last_name": "Stemmy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-01-01", "end_date": "2022-12-31", "award_amount": 292710, "principal_investigator": { "id": 18871, "first_name": "WEI", "last_name": "WENG", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 919, "ror": "", "name": "INGENIOUS TARGETING LABORATORY, INC.", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "With the initial wave of zoonotic transmission firmly established in the human population worldwide, severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) poses an eminent threat to individuals, health care systems and societies. Various degrees of disease severity (from asymptomatic to lethal) combined with challenging infection metrics ‒ in the absence of widespread testing coverage, as well as lack of established vaccination and treatment options ‒ have triggered massive and urgent biomedical efforts to counter the associated human disease that is COVID-19. Founded in the complexities of virus/host interactions, it is imperative to utilize experimental infections with virus or viral material in translational platforms with a focus on viral and/or host modeling in order to establish preventive as well as control strategies. In this experimental setting, animal models play a central role as in vivo hosts for evaluation purposes of antiviral drugs, immunotherapy and vaccines ‒ foremost in preclinical, but also in parallel-to-clinical, studies. A single type of organism, either wildtype or genetically-modified, will however likely not be sufficient for studies of all relevant physiological mechanisms. In this project, we propose reverse genetic designs in the mouse by introducing genetically humanized components on large and medium scales, enabling viral binding and cellular infection with the aim to mimic human COVID-19 disease susceptibility during early stages of the SARS-CoV-2 replication cycle. Rodent species, although favorable as small animal research objects, are generally refractory to displaying SARS and the COVID-19 pathology upon simple infection. One way to address this species boundary so far was to create random transgenic mouse lines carrying small-scale partially humanized gene expression units for the human ACE2 receptor. These models, however, display partial phenotypes characterized by: (a) no terminal-lung outcomes, (b) undesired replication in the brain and (c) lack of multi- organ failure upon infection (exemplified by SARS-CoV, with similar outcomes expected for SARS-CoV-2). In order to enable a distinct lung and other human phenotypes, we hypothesize that extended genomic humanization in the form of the human ACE2 receptor alone (see Spec. Aim 1) or in combination with lung- specific human cofactors, i.e., TMPRSS2/Furin (see Spec. Aim 2) ‒ based on their human-like expression (verified in Spec. Aim 3) ‒ will thus improve viral infection and tissue tropism measured by timely progression of viral titers in different organs (in Spec. Aim 4). Fluorescent reporting as well as site-specific recombination will be enabled in an alternative Cre-recombinase fusion model of ACE2, while intrinsic features of the TMPRSS2/Furin model will provide a fluorescent signal upon expression. Our broad SARS/COVID-19 mouse model platform utility (consisting of three individual models at the Phase I stage) will significantly support cross- species translational investigations into the development of disease and the testing of intervention measures by specialists in the biomedical field ‒ thus, addressing their short-term and long-term research needs.", "keywords": [ "2019-nCoV", "ACE2", "Address", "Animal Experimentation", "Animal Model", "Animals", "Antiviral Agents", "Bacterial Artificial Chromosomes", "Binding", "Body Weight decreased", "Brain", "COVID-19", "Clinical Research", "Clone Cells", "Communities", "Complementary DNA", "Containment", "Coronavirus", "Detection", "Development", "Disease", "Disease Outbreaks", "Disease Progression", "Disease susceptibility", "Embryo", "Enabling Factors", "Engineering", "Enterobacteria phage P1 Cre recombinase", "Etiology", "Evaluation", "Exons", "Future", "Gene Expression", "Genes", "Genetic", "Genetic Recombination", "Genetically Engineered Mouse", "Genome", "Genomics", "Genotype", "Health", "Healthcare Systems", "Human", "Immunotherapy", "Individual", "Infection", "Infectious Agent", "Integration Host Factors", "Intervention", "Introns", "Investigation", "Investigational Therapies", "K-18 conjugate", "Kinetics", "Knowledge", "Laboratories", "Licensing", "Life Cycle Stages", "Logic", "Lung", "Measures", "Mediating", "Medical", "Modeling", "Modification", "Monitor", "Multiple Organ Failure", "Mus", "Organ", "Organism", "Outcome", "Pathogenesis", "Pathology", "Peptide Hydrolases", "Pharmaceutical Preparations", "Phase", "Phenotype", "Physiological", "Play", "Population", "Predisposition", "Prevention", "Preventive", "Preventive measure", "Production", "Protein Isoforms", "Protein S", "Proteins", "Public Health", "RNA Splicing", "Refractory", "Regulation", "Regulatory Element", "Reporter", "Reporting", "Reproducibility", "Research", "Research Personnel", "Reverse Transcriptase Polymerase Chain Reaction", "Rodent", "Role", "SARS coronavirus", "Severe Acute Respiratory Syndrome", "Severity of illness", "Shapes", "Signal Transduction", "Site", "Small Business Innovation Research Grant", "Societies", "Specialist", "Structure", "System", "TMPRSS2 gene", "Testing", "The Jackson Laboratory", "Time", "Transcript", "Transgenic Mice", "Transgenic Organisms", "Tropism", "Vaccination", "Vaccines", "Validation", "Viral", "Viral Load result", "Virion", "Virus", "Virus Diseases", "Zoonoses", "base", "cofactor", "design", "drug discovery", "embryonic stem cell", "human disease", "improved", "in vivo", "innovation", "interest", "mouse genome", "mouse model", "novel coronavirus", "offspring", "pandemic disease", "particle", "pathogen", "pre-clinical", "promoter", "receptor", "response", "reverse genetics", "socioeconomics", "stressor", "tissue tropism", "too" ], "approved": true } }, { "type": "Grant", "id": "5504", "attributes": { "award_id": "3U54AI142766-04S1", "title": "A 3D Tissue Map of the Human Lymphatic System", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 19154, "first_name": "Kentner L.", "last_name": "Singleton", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2020-09-08", "end_date": "2022-06-30", "award_amount": 433718, "principal_investigator": { "id": 19155, "first_name": "MARK A.", "last_name": "ATKINSON", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 19156, "first_name": "Bernd", "last_name": "Bodenmiller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 19157, "first_name": "HARRY S", "last_name": "NICK", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 158, "ror": "https://ror.org/02y3ad647", "name": "University of Florida", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true }, "abstract": "The lymphatic system serves five primary roles: 1) removal of excess body fluids; 2) absorption and transport of fatty acids/chyle to the circulatory system; 3) blood filtration; 4) mounting the primary defense against infections and cancer through immune cell production and activation; and 5) generation and activation of regulatory immune cells that protect against autoimmune/autoinflammatory disease. Given these key physiological functions, we deem it important to develop a three-dimensional (3D) tissue map for three major lymphoid organs of the human immune system: spleen, thymus and lymph nodes (Organ Specific Projects 1- 3, respectively). As one of our primary strengths, we have over 10 years of experience in the procurement of transplant-quality organs for research, including those of the lymphatic system. As part of this 24/7/365 effort, we have well-established relationships with the U.S. Organ Procurement Organizations (OPO), having referrals from 56/58 over the last decade. Our standard operating procedures (SOPs), both published and web-based, include assessment of normality, quality control assays, and systematic anatomical dissection/storage. We also participate in National QA/QC programs to evaluate tissue processing/banking procedures. Our approach to developing assay pipelines towards the common goal of a 3D tissue map will initially involve acquiring a macro image of the intact tissue and addressing tissue morphology, using our strengths in magnetic resonance imaging (MRI). The proposed optical microscopy pipeline will address microanatomical features using formalin fixed paraffin embedded (FFPE) and optimal cutting temperature (OCT) compound embedded sections as well as tissue optical clearing and expansion. These specimens will be studied from nm to mm resolution using stochastic optical reconstruction microscopy (STORM), confocal, multiphoton and light sheet fluorescence microscopies (LSFM), with all pipelines sharing a common file format for simplified 3D reconstruction. Based on the unique role for lymphatic organs in production and trafficking of immune cells, fluorescence activated cell sorting (FACS) of cells from blood and each lymphatic organ will provide a comparison of the patient- specific immune cell repertoire and serve in subsequent single cell RNA-seq analyses. To co-register biomolecules to their cognate cells, we will employ imaging mass cytometry (IMC), multiplex single molecule fluorescence in situ hybridization (smFISH) and multiplexed error-robust FISH (MERFISH) to map cellular protein and mRNA expression, ultimately on each 3D tissue atlas. Our experience in organ procurement, the availability of the National High Magnetic Field Laboratory (NHML) Advanced Magnetic Resonance Imaging and Spectroscopy (AMRIS) Facility at UF, multiphoton/confocal microscopy, LSFM, state of the art FACS, 10X GENOMICS Chromium controller, and high throughput cDNA library sequencing for RNA-Seq at the University of Florida, as well as world leading IMC and 3D data analysis facility at the University of Zurich, ideally positions us to provide the highest quality 3D Human BioMolecular Atlas (HuBMAP) of the lymphatic organs.", "keywords": [ "3-Dimensional", "Address", "Advisory Committees", "Aging", "Algorithms", "Anatomy", "Antigen-Presenting Cells", "Architecture", "Atlases", "Autoimmune", "B-Lymphocytes", "Back", "Biological Assay", "Blood", "Blood Circulation", "Body Fluids", "Body fat", "Cardiovascular system", "Cell Separation", "Cells", "Chromium", "Chyle", "Clinical Data", "Collaborations", "Communities", "Confocal Microscopy", "Consultations", "Coupled", "Cytometry", "Data", "Data Analyses", "Data Files", "Dendritic Cells", "Diabetes Mellitus", "Discontinuous Capillary", "Disease", "Dissection", "Drainage procedure", "Erythrocytes", "Excision", "Exclusion Criteria", "Florida", "Flow Cytometry", "Fluorescence Microscopy", "Fluorescence-Activated Cell Sorting", "Fluorescent in Situ Hybridization", "Formalin", "Fostering", "Generations", "Goals", "Housing", "Human", "Human BioMolecular Atlas Program", "Human body", "IgG2", "Image", "Immune", "Immune response", "Immune system", "Immunity", "Immunoglobulin M", "Immunohistochemistry", "Immunologic Surveillance", "In Situ Hybridization", "Infection", "Invaded", "Knowledge", "Laboratories", "Leukocytes", "Life", "Light", "Link", "Lobular", "Longevity", "Lymph", "Lymphatic System", "Lymphatic function", "Lymphocyte", "Magnetic Resonance Imaging", "Malignant Neoplasms", "Malpighian corpuscles", "Maps", "Messenger RNA", "Microscopy", "Morphology", "Normalcy", "Online Systems", "Optics", "Organ", "Organ Donor", "Organ Procurements", "Organism", "Pancreas", "Paraffin Embedding", "Pathologist", "Patients", "Periarteriolar Lymphoid Sheath", "Peripheral", "Physiological", "Positioning Attribute", "Pregnancy", "Procedures", "Production", "Proliferating", "Protocols documentation", "Publishing", "Quality Control", "Recording of previous events", "Reproducibility", "Research", "Research Personnel", "Resolution", "Reticular Cell", "Rodent", "Role", "Series", "Site", "Specimen", "Spleen", "Splenic Red Pulp", "Stains", "Stretching", "Structure", "Structure of germinal center of lymph node", "Structure of thymic cortex", "System", "T-Cell Development", "T-Lymphocyte", "Temperature", "Thymus Gland", "Tissues", "Transplantation", "United States National Institutes of Health", "Universities", "Vascular blood supply", "Veins", "Visualization", "Work", "absorption", "arteriole", "autoinflammatory", "base", "blood filter", "blood filtration", "cDNA Library", "cancer cell", "data sharing", "daughter cell" ], "approved": true } }, { "type": "Grant", "id": "10773", "attributes": { "award_id": "1K01HL163254-01A1", "title": "ActivityChoice: A clinic-delivered implementation program to increase physical activity and decrease cardiovascular disease risk amongst cancer survivors", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 6203, "first_name": "Sean", "last_name": "Coady", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-12-13", "end_date": "2026-11-30", "award_amount": 162485, "principal_investigator": { "id": 26845, "first_name": "Jamie", "last_name": "Faro", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 790, "ror": "", "name": "UNIV OF MASSACHUSETTS MED SCH WORCESTER", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Cancer survivors have 1.7-18.5-fold increased risk, and 1.3-3.6-fold increased mortality of cardiovascular disease (CVD). Physical activity has been shown to ameliorate risk, but survivors’ levels are far below the general population. Due to this, provider physical activity recommendations and referrals are recommended by the Institute of Medicine and the American Heart Association in survivorship care plans. In light of these recommendations, barriers to physical activity participation among survivors exist at the provider, community, and survivor levels. There is a critical need for implementation programs to connect these resources to increase physical activity among survivors. To address this need, I developed, and beta tested a clinic-based eReferral system referring patients to a nationwide community-based group program, LIVESTRONG at the Y, for survivors. Due to COVID-19, we also referred to a virtual group program, Fit Cancer. The beta-test revealed the potential of this approach; providers were engaged and referred survivors to the physical activity programs. It also revealed the need for the eReferral to provide physical activity program choices, including a non-group self- monitored digital health program. We, therefore, will build on the prior eReferral to develop and test ActivityChoice in this 4-year proposal. ActivityChoice will include a patient narrative decision aid to support choices to three evidence-based programs: LIVESTRONG (group in-person), Fit Cancer (group virtual), and CareEvolution (Fitbit activity tracking and tailored messaging digital health). We found survivors prefer to hear personal stories and support from other survivors to help support activity adoption, thus our decision aid will include patient narrative stories to support program choices. In Aim 1, we will develop and test patient decision aids to support choices with survivors and clinic staff and refine ActivityChoice. In Aim 2, we will conduct a stepped wedge trial with clinic staff (n=8) at 3 UMass Cancer clinics sites, comparing an enhanced standard of care control to the ActivityChoice implementation program in 70 patients with survivorship care planning visits. We hypothesize ActivityChoice will have greater referral rates as compared to the enhanced standard of care control. We will assess additional implementation outcomes, as well as exploratory physical activity and patient- reported outcomes. In Aim 3, we will refine ActivityChoice and prepare for a multi-site trial through interviews with stakeholders (survivors, clinic staff and administration) and potential future sites identified through our collaborative networks. The refined program will be tested in a fully-powered effectiveness R01 trial submitted in Year 4 of this project. To accomplish these aims, I will be guided by expert mentors and receive specialized training in 1) Health and patient-provider communication, 2) Digital Health, 3) Advanced pragmatic clinical trials and 4) Leadership and grant-development. This project will be conducted in collaboration with our clinical, community and patient partners (Community Advisory Board) to guide the overall project design.", "keywords": [ "Address", "Adoption", "Aftercare", "American Heart Association", "COVID-19", "Cancer Survivor", "Cancer Survivorship", "Cardiovascular Diseases", "Caring", "Cause of Death", "Clinic", "Clinical", "Collaborations", "Communities", "Computerized Medical Record", "Data", "Decision Aid", "Development", "Effectiveness", "Enrollment", "Evidence based program", "Feedback", "Future", "General Population", "Grant", "Health", "Hearing", "Institute of Medicine (U.S.)", "Intervention", "Interview", "Leadership", "Letters", "Light", "Malignant Neoplasms", "Mentors", "Monitor", "Outcome", "Paper", "Participant", "Pathway interactions", "Patient Outcomes Assessments", "Patient-Focused Outcomes", "Patients", "Persons", "Physical activity", "Practical Robust Implementation and Sustainability Model", "Pragmatic clinical trial", "Process", "Protocols documentation", "Provider", "Recommendation", "Regulation", "Reporting", "Research Personnel", "Resources", "Risk", "Risk Factors", "Role playing therapy", "SECTM1 gene", "Secure", "Self Determination", "Site", "Surveys", "Survivors", "System", "Testing", "Time", "Training", "Uncertainty", "United States", "Visit", "Walking", "Work", "base", "cancer diagnosis", "cardiovascular disorder risk", "clinical implementation", "design", "digital health", "evidence base", "experience", "fitbit", "flyer", "follow-up", "health related quality of life", "implementation outcomes", "meetings", "mortality", "multi-site trial", "novel", "patient engagement", "patient oriented", "patient-clinician communication", "pilot test", "pragmatic trial", "prevent", "programs", "randomized trial", "sedentary", "skills", "stakeholder perspectives", "standard of care", "support tools", "survivorship", "tailored messaging", "tool", "virtual" ], "approved": true } }, { "type": "Grant", "id": "5558", "attributes": { "award_id": "5UH3MH114249-05", "title": "Mechanisms underlying resilience to neighborhood disadvantage", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Mental Health (NIMH)" ], "program_reference_codes": [], "program_officials": [ { "id": 19290, "first_name": "Ashley", "last_name": "Smith", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2017-09-01", "end_date": "2023-06-30", "award_amount": 853587, "principal_investigator": { "id": 19291, "first_name": "S. Alexandra", "last_name": "Burt", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 19292, "first_name": "Luke Williamson", "last_name": "Hyde", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 521, "ror": "https://ror.org/05hs6h993", "name": "Michigan State University", "address": "", "city": "", "state": "MI", "zip": "", "country": "United States", "approved": true }, "abstract": "Decades of research have confirmed the damaging effects of neighborhood disadvantage on physical, socioeconomic, and mental health outcomes. Even so, many children growing up in disadvantaged neighborhood contexts demonstrate adaptive competence. How do children achieve these resilient outcomes in the face of such adversity? Extant studies indicate that familial- and community-level factors protect these children from the many stressors found in disadvantaged neighborhoods. Very little work, however, has considered the neurobehavioral pathways through which these protective processes confer resilience. The proposed UG3/UH3 will do just this, identifying neural markers of resilience and illuminating the multilevel epigenetic, environmental, and genetic processes through which protective factors promote these neuro-resilient pathways. We propose to re-assess a sample of 500 adolescent twin pairs (at age 11-16 years; previously assessed between ages 6 and 10) residing in modestly-to-severely disadvantaged neighborhoods. We will employ cutting-edge neuroimaging methodologies (i.e., joint models that bridge task and resting fMRI, DTI, and sMRI) to identify the synergistic neural networks that are associated with resilience (operationalized here as adaptive competence and the absence of psychopathology), while also capitalizing on the longitudinal and genetically-informed nature of our unique `at-risk' twin sample to illuminate the etiologic processes underlying neural markers of resilience. We specifically postulate that, by protecting youth from the stressors presents in disadvantage contexts, positive parents and communities enable children to develop the normative neural architecture that undergirds subsequent adaptive outcomes, even in the face of adversity. Our genetically-informed developmental neuroscience approach will thus provide an unprecedented opportunity to illuminate the multilevel biobehavioral pathways leading to resilience, and in this way, fundamentally advance our understanding of adaptation in the face of chronic adversity.", "keywords": [ "Adolescent", "Age", "Architecture", "Behavioral", "Brain", "Buffers", "Child", "Child Rearing", "Chronic", "Communities", "Competence", "Decision Making", "Development", "Disadvantaged", "Epigenetic Process", "Etiology", "Family", "Functional Magnetic Resonance Imaging", "Genetic", "Genetic Processes", "Health", "Heritability", "Image", "Joints", "Mediating", "Mental Health", "Methodology", "Methylation", "Modeling", "Monozygotic twins", "Nature", "Neighborhoods", "Neurosciences", "Outcome", "Parents", "Pathway interactions", "Process", "Psychopathology", "Research", "Rest", "Risk", "Sampling", "Shapes", "Social Processes", "Structure", "Time", "Twin Multiple Birth", "Work", "Youth", "base", "biobehavior", "emotion regulation", "epigenetic marker", "independent component analysis", "neighborhood disadvantage", "neural network", "neurobehavioral", "neuroimaging", "prospective", "protective factors", "relating to nervous system", "resilience", "skills", "social cohesion", "socioeconomics", "stressor" ], "approved": true } }, { "type": "Grant", "id": "10723", "attributes": { "award_id": "1R21AI173596-01", "title": "Improving mRNA vaccines with extracellular vesicle-associated immunogens", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6908, "first_name": "JENNIFER L.", "last_name": "Gordon", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-11-09", "end_date": "2024-10-31", "award_amount": 289800, "principal_investigator": { "id": 21748, "first_name": "Michael R.", "last_name": "Farzan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1472, "ror": "", "name": "SCRIPPS FLORIDA", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 158, "ror": "https://ror.org/02y3ad647", "name": "University of Florida", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true }, "abstract": "The central hypothesis of this proposal is that the efficacy of mRNA vaccines that deliver membrane-anchored immunogens can be improved by localizing the immunogen to extracellular vesicles (EVs, small membrane- limited structures shed by eukaryotic cells). Our rationale is that EVs provide a natural scaffold for immunogen multimerization while also enabling membrane-bound antigens to access antigen presenting cells, both local to the site of injection, and in the draining lymph node. To localize immunogens to EVs and promote EV shedding we propose two complimentary approaches. In Aim 1, we will append a viral “late domain” to the carboxy terminus of our immunogen. Viral late domains are small protein domains, usually associated with a matrix or capsid protein, used by enveloped viruses to facilitate budding and egress. We have found that these domains can act out of context; fusing a late domain from feline immunodeficiency virus Gag to a SARS-CoV-2 spike protein immunogen caused the immunogen to re- localize to EVs and improved its immunogenicity nearly two-fold. We will expand this work by testing late domains from other viruses for their ability to promote EV localization and/or production. We will thoroughly characterize these EVs to determine correlates of vaccine immunogenicity. In Aim 2, we will modify our immunogens to overcome the activity of the host anti-viral restriction factor BST-2 (a.k.a. tetherin). Tetherin inhibits viral egress by “tethering” budding enveloped viruses to the host cell membranes and also inhibits the release of EVs by the same mechanism. Therefore, we will explore strategies for antagonizing tetherin in order to promote release of our immunogen-laden EVs. Enveloped viruses have evolved different strategies for tetherin evasion that we will attempt to incorporate into our immunogen designs. Indeed, we have identified a portion of the SARS-CoV-2 spike protein that we suspect is responsible for tetherin antagonism. Incorporating this S protein domain into our immunogen dramatically increases the amount of immunogen recovered from EV fractions of tissue culture supernatants. We will also explore similar strategies based on tetherin resistance mechanisms from other viruses. Finally, in Aim 3, promising immunogen design strategies in the context of different viral envelope protein immunogens (SARS-CoV-2, influenza A virus, HIV) will be compared in mice. These tests will allow us to establish correlations between the behavior of our vaccine immunogens in tissue culture (quantity and characteristics of the EVs, cytoxicity, etc.) and performance of the vaccine in vivo and determine if our modifications universally improve vaccine efficacy, or if particular immunogen designs are better suited for specific viral antigens.", "keywords": [ "2019-nCoV", "Adenovirus Vector", "Animals", "Antibody Formation", "Antibody Response", "Antibody titer measurement", "Antigen-Presenting Cells", "Antigens", "Behavior", "COVID-19", "COVID-19 vaccine", "Capsid Proteins", "Carrier Proteins", "Cell Fraction", "Cell Line", "Cell membrane", "Cells", "Characteristics", "Communicable Diseases", "DNA", "Data", "Development", "Dose", "Effectiveness", "Eukaryotic Cell", "Feline Immunodeficiency Virus", "Fluzone", "Formulation", "Glycoproteins", "HIV", "HIV-1", "Hemagglutinin", "Human", "Immune", "Improve Access", "Influenza A virus", "Injections", "Interferons", "Membrane", "Messenger RNA", "Modification", "Molecular Conformation", "Mus", "Nonstructural Protein", "Patients", "Performance", "Preparation", "Production", "Proteins", "RNA vaccine", "Recombinants", "Reporting", "Resistance", "Route", "SARS-CoV-2 spike protein", "Sampling", "Serum", "Site", "Structure", "Subunit Vaccines", "Tail", "Tertiary Protein Structure", "Testing", "Translating", "Vaccinated", "Vaccines", "Viral", "Viral Antigens", "Viral Envelope Proteins", "Viral Matrix Proteins", "Viral Proteins", "Viral Vaccines", "Virus", "Virus Diseases", "Work", "adaptive immunity", "antagonist", "antigen binding", "antigen test", "base", "cellular transduction", "chicken egg", "design", "draining lymph node", "efficacy testing", "env Gene Products", "exosome", "experimental study", "extracellular vesicles", "immunogenic", "immunogenicity", "improved", "in vivo", "influenza virus vaccine", "interest", "iterative design", "lipid nanoparticle", "manufacturing process", "microvesicles", "panacea", "pathogen", "prevent", "process optimization", "resistance mechanism", "response", "scaffold", "success", "tissue culture", "vaccine delivery", "vaccine efficacy", "vaccine immunogenicity", "vaccine platform", "vector vaccine", "virus envelope" ], "approved": true } }, { "type": "Grant", "id": "10705", "attributes": { "award_id": "1U01MD018306-01", "title": "Leveraging artificial intelligence and social innovation to reduce disparities in COVID-19 testing among African Americans", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 6029, "first_name": "JARRETT AINSWORTH", "last_name": "Johnson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2022-11-01", "end_date": "2024-10-31", "award_amount": 555475, "principal_investigator": { "id": 20638, "first_name": "Tiarney D", "last_name": "Ritchwood", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 246, "ror": "https://ror.org/00py81415", "name": "Duke University", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 4, "pages": 1405, "count": 14046 } } }